Polycystic ovary syndrome, the forgotten cardiovascular risk
DOI:
https://doi.org/10.18041/2665-427X/ijeph.1.10262Keywords:
Cardiovascular risk, Obesity, Polycystic ovary syndrome, ManagementAbstract
Polycystic ovary syndrome (PCOS) is a very prevalent disorder in women of fertile age. It is accompanied by aesthetic manifestations such as acne and hirsutism and some cardiovascular risk (CVR) implications, such as obesity, insulin resistance, inflammation as well as increased oxidative stress. It has been widely linked as an independent CVR factor, which should be diagnosed and treated with the same importance as other conditions, such as hypertension, diabetes, and dyslipidemia. Regarding treatment, there are no large studies; however, an important component is the impact on weight and metabolic variables. Options such as lifestyle and pharmacological measures can be considered, including the use of metformin, empagliflozin, liraglutide, and semaglutide, as well as interventions such as weight control surgery in those patients with significant obesity and other CVR factors. We bring an insight into this often forgotten CVR, evaluating its epidemiology, pathophysiological factors, and treatment.
Downloads
References
Azziz R. Polycystic Ovary Syndrome. Obstet Gynecol. 2018; 132(2): 321-336. doi: 10.1097/AOG.0000000000002698.
Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998; 83(9): 3078-82. doi: 10.1210/jcem.83.9.5090.
Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935; 29(2): 181–91. doi: 10.1016/S0002-9378(15)30642-6
McLuskie I, Newth A. New diagnosis of polycystic ovary syndrome. BMJ. 2017; 356: i6456. doi: 10.1136/bmj.i6456.
Bilal M, Haseeb A, Rehman A. Relationship of polycystic ovarian syndrome with cardiovascular risk factors. Diabetes Metab Syndr. 2018; 12(3): 375-380. doi: 10.1016/j.dsx.2018.01.006.
DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005; 83(5): 1454-60. doi: 10.1016/j.fertnstert.2004.11.070.
Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001; 111(8): 607-13. doi: 10.1016/s0002-9343(01)00948-2.
Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf). 2000; 52(5): 595-600. doi: 10.1046/j.1365-2265.2000.01000.x.
Krentz AJ, von Mühlen D, Barrett-Connor E. Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease. Menopause. 2007; 14(2): 284-92. doi: 10.1097/GME.0b013e31802cc7ab.
McCartney CR, shall JC. Clinical Practice. Polycystic ovary syndrome. N Engl J Med. 2016; 375(1): 54-64. doi: 10.1056/NEJMcp1514916.
Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004; 89(6): 2745-9. doi: 10.1210/jc.2003-032046.
Sadeghi HM, Adeli I, Calina D, Docea AO, Mousavi T, Daniali M, et al. Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. Int J Mol Sci. 2022; 23(2): 583. doi: 10.3390/ijms23020583.
Lu ME, Chizen DR, Pierson RA. Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies. J Obstet Gynaecol Can. 2008; 30(8): 671-679. doi: 10.1016/S1701-2163(16)32915-2.
Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41-7. doi: 10.1093/humrep/deh098.
National Institute of Health. Evidence-based Methodology Workshop on Polycystic Ovary Syndrome. National Institute of Health; 2012.
Available from: https://prevention.nih.gov/sites/default/files/2018-06/FinalReport.pdf
Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013; 98(12): 4565-92. doi: 10.1210/jc.2013-2350.
Belenkaia LV, Lazareva LM, Walker W, Lizneva DV, Suturina LV. Criteria, phenotypes and prevalence of polycystic ovary syndrome. Minerva Ginecol. 2019; 71(3): 211-223. doi: 10.23736/S0026-4784.19.04404-6.
Dumesic DA, Oberfield SE, Stener-Victorin E, shall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015; 36(5): 487-525. doi: 10.1210/er.2015-1018.
Moran C, Tena G, Moran S, Ruiz P, Reyna R, Duque X. Prevalence of polycystic ovary syndrome and related disorders in mexican women. Gynecol Obstet Invest. 2010; 69(4): 274-80. doi: 10.1159/000277640.
Gabrielli L, Aquino EM. Polycystic ovary syndrome in Salvador, Brazil: a prevalence study in primary healthcare. Reprod Biol Endocrinol. 2012; 10: 96. doi: 10.1186/1477-7827-10-96.
Espitia-De La Hoz FJ. Características clínicas, hormonales, bioquímicas y prevalencia del síndrome de ovario poliquístico en mujeres del Eje Cafetero, Colombia, 2016-2020. Rev Colomb Endocrinol Diabet Metab. 2022; 9(4): e772. doi: 10.53853/encr.9.4.772
Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010; 95(5): 2038-49. doi: 10.1210/jc.2009-2724.
Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016; 31(12): 2841-2855. doi: 10.1093/humrep/dew218.
Berni TR, Morgan CL, Rees DA. Women with polycystic ovary syndrome have an increased risk of major cardiovascular events: a population study. J Clin Endocrinol Metab. 2021; 106(9): e3369-e3380. doi: 10.1210/clinem/dgab392.
Wekker V, van Dammen L, Koning A, Heida KY, Painter RC, Limpens J, et al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2020; 26(6): 942-960. doi: 10.1093/humupd/dmaa029.
Legro RS, Chiu P, Kunselman AR, Bentley CM, Dodson WC, Dunaif A. Polycystic ovaries are common in women with hyperandrogenic chronic aulation but do not predict metabolic or reproductive phenotype. J Clin Endocrinol Metab. 2005; 90(5): 2571-9. doi: 10.1210/jc.2004-0219.
Welt CK, Gudmundsson JA, Arason G, Adams J, Palsdottir H, Gudlsdottir G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab. 2006; 91(12): 4842-8. doi: 10.1210/jc.2006-1327.
Jones H, Sprung VS, Pugh CJ, Daousi C, Irwin A, Aziz N, et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2012; 97(10): 3709-16. doi: 10.1210/jc.2012-1382.
Guastella E, Longo RA, Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril. 2010; 94(6): 2197-201. doi: 10.1016/j.fertnstert.2010.02.014.
Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010; 95(5): 2038-49. doi: 10.1210/jc.2009-2724.
Luque-Ramírez M, Alpañés M, Sanchón R, Fernández-Durán E, Ortiz-Flores AE, Escobar-Morreale HF. Referral bias in female functional hyperandrogenism and polycystic ovary syndrome. Eur J Endocrinol. 2015; 173(5): 603-10. doi: 10.1530/EJE-15-0646.
Hyderali BN, Mala K. Oxidative stress and cardiovascular complications in polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol. 2015; 191: 15-22. doi: 10.1016/j.ejogrb.2015.05.005.
Madamanchi NR, Runge MS. Redox signaling in cardiovascular health and disease. Free Radic Biol Med. 2013; 61: 473-501. doi: 10.1016/j.freeradbiomed.2013.04.001.
Neves LPP, condes RR, Maffazioli GN, Simões RS, Maciel GAR, Soares JM Jr, et al. Nutritional and dietary aspects in polycystic ovary syndrome: insights into the biology of nutritional interventions. Gynecol Endocrinol. 2020; 36(12): 1047-1050. doi: 10.1080/09513590.2020.1822797.
Che X, Chen Z, Liu M, Mo Z. Dietary Interventions: A Promising Treatment for Polycystic Ovary Syndrome. Ann Nutr Metab. 2021; 77(6): 313-323. doi: 10.1159/000519302.
Kite C, Lahart IM, Afzal I, Broom DR, Randeva H, Kyrou I, Brown JE. Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis. Syst Rev. 2019; 8(1): 51. doi: 10.1186/s13643-019-0962-3.
Naderpoor N, Shorakae S, de Courten B, Misso ML, Moran LJ, Teede HJ. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update. 2015; 21(5): 560-74. doi: 10.1093/humupd/dmv025.
Heidari B, Lerman A, Lalia AZ, Lerman LO, Chang AY. Effect of Metformin on Microvascular Endothelial Function in Polycystic Ovary Syndrome. o Clin Proc. 2019; 94(12): 2455-2466. doi: 10.1016/j.ocp.2019.06.015.
Javed Z, Papageorgiou M, Deshmukh H, Rigby AS, Qa U, Abbas J, et al. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. Clin Endocrinol (Oxf). 2019; 90(6): 805-813. doi: 10.1111/cen.13968.
Elkind-Hirsch KE, Chappell N, Shaler D, Storment J, Bellanger D. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertil Steril. 2022; 118(2): 371-381. doi: 10.1016/j.fertnstert.2022.04.027.
Jensterle M, Fer S, Vovk A, Battelino T, Rizzo M, ež A. Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study. Diabetes Res Clin Pract. 2021; 178: 108935. doi: 10.1016/j.diabres.2021.108935.
Yue W, Huang X, Zhang W, Li S, Liu X, Zhao Y, et al. Metabolic surgery on patients with polycystic ovary syndrome: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022; 13: 848947. doi: 10.3389/fendo.2022.848947.
Hu L, Ma L, Xia X, Ying T, Zhou M, Zou S, et al. Efficacy of bariatric surgery in the treatment of women with obesity and polycystic ovary syndrome. J Clin Endocrinol Metab. 2022; 107(8): e3217-e3229. doi: 10.1210/clinem/dgac294.
Bashir R, Asrar MM, Ahmad Shah I, A Wani I, Ganie MA. Do pleiotropic effects of spironolactone in women with pcos make it more than an anti-androgen? evidence from a systematic review and meta-analysis. Curr Pharm Des. 2023; 29(19): 1486-1496. doi: 10.2174/1381612829666230331093912.
Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023; 189(2): G43-G64. doi: 10.1093/ejendo/lvad096.
Ramezani Tehrani F, Amiri M, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol. 2020; 36(1): 12-23. doi: 10.1080/09513590.2019.1650337.
Downloads
Published
Versions
- 2024-05-08 (4)
- 2023-12-30 (3)
- 2023-06-30 (2)
- 2023-06-30 (1)
Issue
Section
License
Copyright (c) 2023 Interdisciplinary Journal of Epidemiology and Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
-
NonCommercial — You may not use the material for commercial purposes.
-
NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
